Taysha Gene Therapies, Inc. (TSHA)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Sean P. Nolan | CEO & Chairman | 1.03M | -- | 1968 |
| Dr. Sukumar Nagendran M.D. | President, Head of Research & Development and Director | 907.17k | -- | 1967 |
| Mr. Kamran Alam CPA, M.B.A. | CFO & Corporate Secretary | 676.69k | -- | 1978 |
| Hayleigh Collins | Director of Corporate Communications & Investor Relations | -- | -- | -- |
| Ms. Tracy M. Porter SPHR | Chief People Officer | -- | -- | -- |
| Mr. Frederick Porter Ph.D. | Chief of Staff & Technical Operations Officer | -- | -- | -- |
| Ms. Emily McGinnis M.P.H. | Chief Patient & External Affairs Officer | -- | -- | -- |
| Mr. Sean McAuliffe | Chief Business Officer | -- | -- | -- |
| Dr. Steven Gray Ph.D. | Chief Scientific Advisor of UT Southwestern Gene Therapy Program | -- | -- | -- |
| Berge Minassian M.D. | Chief Medical Advisor of UT Southwestern Gene Therapy Program | -- | -- | -- |
Taysha Gene Therapies, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 73
Description
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Corporate Governance
Upcoming Events
August 11, 2025 at 12:30 PM UTC - August 15, 2025 at 12:30 PM UTC
Taysha Gene Therapies, Inc. Earnings Date
Recent Events
December 20, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
December 19, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission